AG真人官方

Dyadic International (DYAI) is raising $5.75 million gross through a firmly-underwritten public offering of 6,052,000 common shares at $0.95, a 19% discount to the 29-Jul-25 close ($1.175). Net proceeds are estimated at $5.35 million after $0.40 million underwriting fees/expenses and will be used for working capital, product development, and sales & marketing; management retains full discretion over deployment.

The deal enlarges the share count 20% to 36.1 million and lifts pro-forma tangible book value from $0.03 to $0.17 per share, but new investors face immediate $0.78 dilution. Craig-Hallum receives 302,600 five-year warrants at $1.0925.

Nasdaq compliance remains a critical overhang. DYAI received notices in Jun-25 (market-value < $35 m) and Jul-25 (bid-price < $1) and has until 20-Dec-25 and 13-Jan-26, respectively, to cure or face potential delisting. The raise modestly improves market-cap but does not itself resolve either metric.

President/COO Joseph Hazelton signals insider support by buying 26,000 shares in the offering. Post-offering float remains under $75 m, allowing the company to keep using the S-3 鈥渂aby shelf.鈥�

No changes to strategy were disclosed; Dyadic continues to commercialize its C1 and Dapibus鈩� microbial protein platforms across life-sciences, food, and bio-industrial markets while pursuing funded pharma collaborations.

On 29 Jul 2025, Identiv (INVE) director James E. Ousley reported the acquisition of 28,701 common shares via a grant of Restricted Stock Units (RSUs) under the company鈥檚 2011 Incentive Compensation Plan. The RSUs vest 1/12 each month beginning 1 Jun 2025; vested shares will be delivered on the earlier of (i) three years from the vesting start date or (ii) separation from service. The grant was booked at $0.00, indicating it is part of routine director compensation rather than an open-market purchase. Following the transaction, Ousley鈥檚 direct beneficial ownership rises to 285,456 shares, of which 26,310 are still unvested RSUs. No derivative transactions were reported. The filing shows continued equity alignment between the director and shareholders but does not involve immediate cash outlay or signal a change in company fundamentals.

On 14 July 2025, Range Resources Corporation (NYSE: RRC) filed a Form 8-K (Item 2.02) disclosing preliminary second-quarter 2025 hedging results.

• Total gain on derivatives: approximately $154.7 million for the three months ended 30 June 2025.
• Net cash receipts from derivative settlements: $31.5 million, broken down as $26.3 million from natural gas, $2.8 million from natural-gas-basis, $1.5 million from NGLs and $0.8 million from oil contracts.

The company emphasized that these figures are preliminary and will be finalized in the forthcoming Form 10-Q and related earnings release. No additional operating metrics were provided.

The sizeable mark-to-market gain and positive cash settlements are expected to enhance reported earnings and liquidity for Q2 2025, although such benefits are inherently volatile and tied to future commodity-price movements.

Mobileye Global Inc. (MBLY) filed a Form 4 showing that Boaz Ouriel, Executive Vice President of EPG Software, was granted 111,150 Class A common shares in the form of restricted stock units (RSUs) on 10 July 2025. The transaction was coded 鈥淎,鈥� indicating an equity award rather than an open-market trade, and carried a reported price of $0.

After the grant, Ouriel鈥檚 direct beneficial ownership rises to 219,003 shares. The RSUs carry a 40-30-30 vesting schedule: 40 % on the first anniversary of the grant date, 30 % on the second, and 30 % on the third, contingent upon continued employment. No derivative securities or dispositions were reported.

The filing reflects routine executive compensation designed to retain talent and align management incentives with long-term shareholder interests. Given Mobileye鈥檚 large outstanding share base, the incremental dilution from 111,150 shares is unlikely to be material, and the grant does not involve any cash outlay or immediate change in market float.

Prospect Capital Corporation (PSEC) intends to issue three new series of senior unsecured Prospect Capital InterNotes庐 under its shelf registration (File No. 333-269714):

• 7.500% Notes due 7/15/2028 (CUSIP 74348GWF3)
• 7.750% Notes due 7/15/2030 (CUSIP 74348GWG1)
• 8.000% Notes due 7/15/2032 (CUSIP 74348GWH9)

Each tranche will be sold in $1,000 denominations at modest discounts to par (selling concessions 1.125% / 1.700% / 1.950%) and will accrue interest from the 7/24/2025 settlement date, payable semi-annually on 1/15 and 7/15, commencing 1/15/2026. The notes are callable at 100% of principal beginning 1/15/2026 and daily thereafter. A Survivor鈥檚 Option allows early repayment upon the death of the beneficial owner, subject to annual volume caps.

The offering is being marketed by InspereX (purchasing agent) with Citigroup and RBC Capital Markets as agents. Net proceeds (after concessions) were not disclosed in dollar terms but will be used for general corporate purposes.

Capital structure implications: As of 2/8/2023, PSEC had $1.9 billion of unsecured senior debt and $0.7 billion of secured debt outstanding. The new issuance will add incremental fixed-rate leverage at coupons materially above the company鈥檚 prior 3.7%鈥�6.4% public notes, signalling a higher cost of capital environment. Management recently refinanced its $342.9 million 3.706% 2026 notes鈥攖endering $135.7 million and redeeming the remaining $207.2 million鈥攖hus eliminating that maturity but replacing it with higher-coupon paper.

Recent portfolio activity: Between May 29 and July 1, 2025, PSEC sold $324.6 million (cost basis) of subordinated structured notes for $74.6 million in gross proceeds, extended $39.6 million of first-lien financing to National Property REIT Corp. and received $19 million in repayments. On 6/30/2025 the company closed the acquisition of QC Holdings, Inc., investing $55 million in senior secured debt and $22.3 million in common equity.

Company profile: PSEC is an externally managed BDC with $7.9 billion in assets and 130 portfolio companies/CLO positions as of 12/31/2022. The performing interest-bearing portfolio yielded 12.9% (10.3% overall). The credit facility (outstanding $744.7 million on 2/8/2023) is secured and structurally senior to the new notes.

Key investor considerations:

• High coupons (7.5%-8.0%) increase interest expense but lock in fixed funding before the Federal Reserve鈥檚 next rate cycle shift.
• Notes rank pari passu with existing unsecured obligations and are effectively subordinated to secured debt.
• Indenture contains limited protective covenants; no change-of-control put or financial maintenance tests.
• Liquidity events鈥攃allable at par after 6 months鈥攊ntroduce reinvestment risk if rates fall.

EchoStar Corp. (SATS) 鈥� Form 4 insider activity: On 07/09/2025, Chief Legal Officer Dean A. Manson exercised 25,000 employee stock options at an exercise price of $14.04 (Code M), immediately acquiring the same number of Class A common shares. He then sold the 25,000 shares on the same day at $33.00 per share (Code S). After the transactions, Manson鈥檚 direct holding decreased to 2,322 shares, while he retains 1,106 shares indirectly through a 401(k) and 107,331 unexercised options priced at $14.04 that expire 04/01/2034. The options originally vested 40% at grant, with the remaining 60% vesting 30% each on 04/01/2025 and 04/01/2026. The trades were executed under a Rule 10b5-1 trading plan.

UBS AG is marketing a new structured product, the Trigger Callable Contingent Yield Notes, due July 30, 2029. The notes are unsubordinated, unsecured debt obligations linked to the least-performing of three U.S. equity indices: the Dow Jones Industrial Average, Russell 2000 Index and S&P 500 Index.

Key economic terms:

• Issue price: $1,000 per note; estimated initial value: $939.60 鈥� $969.60 (UBS internal models).
• Contingent coupon: 9.75% p.a. (quarterly $24.375) paid only if the closing level of each index is 鈮� 75 % of its initial level (coupon barrier) on the relevant observation date.
• Issuer call: UBS may call the notes in whole on any quarterly observation date beginning after 6 months; call payment equals par plus any due coupon.
• Downside threshold: 65 % of each index鈥檚 initial level. If not called and any index closes < threshold on final valuation date, maturity payment equals par 脳 (1 + return of worst-performing index), exposing investors to full downside with losses up to 100 %.
• Term: ~4 years (trade date 25 Jul 2025; maturity 30 Jul 2029) with 16 scheduled observation dates.
• Distribution: sold only to fee-based advisory accounts; UBS Securities LLC will pay third-party dealers a $6.00 structuring fee per note.

Risk highlights: Investors may receive no coupons, may lose a significant portion or all principal, face early-call reinvestment risk, lack secondary market liquidity, and are subject to UBS credit risk. The product is not insured by the FDIC and will not be listed on any exchange.

EchoStar Corporation (SATS) 鈥� Insider Form 3 Filing

On 07/08/2025 the Ergen Two-Year June 2025 SATS Grantor Retained Annuity Trust (GRAT) submitted its initial Form 3, designating the trust as a 10% beneficial owner of EchoStar. The filing records ownership of 16,800,000 Class B common shares, each convertible 1-for-1 into Class A shares at no cost. The trust was created by Chairman Charles W. Ergen on 06/26/2025 and is administered by trustee Cantey M. Ergen.

The disclosure represents an internal transfer to an estate-planning vehicle; it does not involve open-market transactions, new share issuance, or a change in EchoStar鈥檚 outstanding share count. Voting and economic control remain within the Ergen family, so no near-term dilution or operational impact is indicated.

On June 20, 2025, Soligenix, Inc. (Nasdaq: SNGX) filed an 8-K summarizing the results of its 2025 Annual Meeting of Stockholders.

• 2025 Equity Incentive Plan: Approved with 215,332 votes For, 91,937 Against and 57,226 Abstain (1,168,832 broker non-votes). Forms of stock option and restricted stock agreements were filed as Exhibits 10.2 and 10.3.
• Board Elections: All five incumbent directors were re-elected. Support ranged from 329,054 to 332,492 votes For; broker non-votes totaled 1,168,832.
• Say-on-Pay: Executive compensation received advisory approval (303,633 For; 53,830 Against; 7,032 Abstain).
• Auditor Ratification: Cherry Bekaert, LLP was ratified for FY 2025 (1,476,465 For; 54,474 Against; 2,388 Abstain).
• Adjournment Authority: Approved with 1,227,450 For; 295,013 Against; 10,864 Abstain.

No operational updates, financial results or major strategic transactions were disclosed; the filing is primarily governance-oriented and does not materially affect near-term fundamentals.